Results 141 to 150 of about 4,277 (167)

CAMEO-a cross-sectional survey study on candidemia management in Germany. [PDF]

open access: yesMed Mycol
Reinhold I   +8 more
europepmc   +1 more source

Bortezomib, Thalidomide, and Dexamethasone Followed by Double Autologous Haematopoietic Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (GIMEMA-MMY-3006): Long-Term Follow-Up Analysis of a Randomised Phase 3, Open-Label Study

Lancet Haematology,the, 2020
The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the ...
Mario Boccadoro   +2 more
exaly   +8 more sources

Multiple Myeloma Mortality Incidence Prevalence of Disease - Mmy Mind Study

Blood, 2020
Background Multiple myeloma (MM) is a heterogeneous and incurable disease that evolves from asymptomatic premalignant conditions. The worldwide incidence, prevalence and mortality are well known thanks to data reported by the International Agency for Research on Cancer (IARC) and by the GLOBOCAN World Cancer Observatory.
Humberto Martínez Cordero   +11 more
openaire   +1 more source

A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma

Blood, 2010
Abstract Abstract 312 Background: Bortezomib (VELCADE®) is approved in the US and Europe for the treatment of patients with multiple myeloma (MM) in both the frontline and the relapse settings.
Moreau, Philippe   +17 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy